Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Phase II, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor to Akt, in Combination With Fluoropyrimidine Plus Oxaliplatin in Patients With Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Trial Profile

A Randomized, Phase II, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor to Akt, in Combination With Fluoropyrimidine Plus Oxaliplatin in Patients With Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipatasertib (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Acronyms JAGUAR
  • Sponsors Genentech
  • Most Recent Events

    • 26 Aug 2019 Planned End Date changed from 30 Jun 2019 to 31 Dec 2020.
    • 24 Dec 2018 Primary endpoint (PFS as Determined by Investigator According to RECIST v1.1 in Participants who Have Phosphatase and Tensin Homolog (PTEN) Loss Tumors or who are Akt Diagnostic-positive (Akt Dx+)) has not been met, according to the results published in the European Journal of Cancer
    • 24 Dec 2018 Primary endpoint (Progression-free Survival (PFS) as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) in All Participants) has not been met, according to the results published in the European Journal of Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top